Analysts Expect Breakeven For Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, is expected to breakeven within the next two years according to industry analysts' expectations. The US$23m market-cap company announced a latest loss of US$16m on 31 December 2024 for its most recent financial year result. As the path to profitability becomes a topic of interest among investors, the company is projected to post a final loss in 2026, before turning a profit of US$750k in 2027.
- The breakeven prediction of Longeveron Inc. highlights the significant growth expectations from analysts, which could be influenced by various factors such as regulatory approvals and market adoption.
- What are the potential risks associated with the company's high growth rate, and how will they impact its ability to deliver on its projections?